These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25444294)

  • 1. Health economic evaluation in England.
    Raftery J
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):367-74. PubMed ID: 25444294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand.
    Teerawattananon Y; Tritasavit N; Suchonwanich N; Kingkaew P
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):397-404. PubMed ID: 25444298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of health economic evaluations in Sweden.
    Heintz E; Arnberg K; Levin LÅ; Liliemark J; Davidson T
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):375-82. PubMed ID: 25444295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
    Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
    Charlton V
    Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The political economy of rationing health care in England and the US: the 'accidental logics' of political settlements.
    Bevan G; Brown LD
    Health Econ Policy Law; 2014 Jul; 9(3):273-94. PubMed ID: 24759205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
    Eddama O; Coast J
    Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries.
    Franken M; Heintz E; Gerber-Grote A; Raftery J
    Value Health; 2016 Dec; 19(8):951-956. PubMed ID: 27987645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not just about costs: the role of health economics in facilitating decision making in aged care.
    Ratcliffe J; Laver K; Couzner L; Cameron ID; Gray L; Crotty M
    Age Ageing; 2010 Jul; 39(4):426-9. PubMed ID: 20444804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How health economic evaluation (HEE) contributes to decision-making in public health care: the case of Brazil.
    Elias FT; Araújo DV
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):405-12. PubMed ID: 25444299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The English and Swedish health care reforms.
    Glennerster H; Matsaganis M
    Int J Health Serv; 1994; 24(2):231-51. PubMed ID: 8034391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intergenerational Report 2015: A limited and political view of our future.
    Kendig H; Woods M
    Australas J Ageing; 2015 Dec; 34(4):217-9. PubMed ID: 26643228
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.